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Background: Angiogenesis is a critical part of the endogenous repair process in brain injury and disease, and
requires at least two sequential steps. First, angiogenic sprouting of endothelial cells occurs, which entails the initial
proliferation of endothelial cells and remodeling of the surrounding extracellular matrix. Second, vessel stabilization
is necessary to prevent vascular regression, which relies on vascular smooth muscle recruitment to surround the
young vessels. Marrow stromal cells (MSCs) have been shown to promote revascularization after hindlimb ischemia,
cardiac ischemia, and stroke. SB623 cells are derived from marrow stromal cells by transfection with a Notch1
intracellular domain (NICD)-expressing plasmid and are known to elicit functional improvement in experimental
stroke. These cells are currently used in human clinical testing for treatment of chronic stroke. In the current study,
the angiogenic property of SB623 cells was investigated using cell-based assays.
Methods: Angiogenic paracrine factors secreted by SB623 cells and the parental MSCs were identified using the
Qantibody Human Angiogenesis Array. To measure the angiogenic activity of conditioned medium from SB623
cells and MSCs, endothelial tube formation in the human umbilical vein endothelial cell (HUVEC) assay and
endothelial cell sprouting and branching in the rodent aortic ring assay were quantified. To validate the angiogenic
contribution of VEGF in conditioned medium, endothelial cells and aortic rings were treated with SU5416, which
inhibits VEGFR2 at low dose.
Results: Conditioned medium from SB623 cells promoted survival and proliferation of endothelial cells under
serum-deprived conditions and supports HUVEC vascular tube formation. In a rodent aortic ring assay, there was
enhanced endothelial sprouting and branching in response to SB623-derived conditioned medium. SU5416
treatment partially reversed the effect of conditioned medium on endothelial cell survival and proliferation while
completely abrogate HUVEC tube formation and endothelial cell sprouting and branching in aortic ring assays.
Conclusions: These data indicate that SB623 cell-secreted angiogenic factors promoted several aspects of
angiogenesis, which likely contribute to promoting recovery in the injured brain.
Keywords: Marrow stromal cells, SB623 cells, Angiogenesis, Stroke, Aortic ring assay, HUVECs* Correspondence: Casey.case@san-bio.com
†Equal contributors
SanBio Inc., 231 South Whisman Road, Mountain View, CA, USA
© 2013 Dao et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Dao et al. Journal of Translational Medicine 2013, 11:81 Page 2 of 11
http://www.translational-medicine.com/content/11/1/81Background
Angiogenesis is the formation of new blood vessels from
existing vasculature. In the adult, angiogenesis occurs
after brain injury as part of the repair and regeneration
process. This process acutely functions to both aid clea-
rance of dead tissue and restore nutrients to surviving
tissue. In the sub-acute and chronic phases, angiogene-
sis accompanies neurogenesis during regeneration [1,2].
The angiogenesis process includes basement membrane
disruption, endothelial cell migration and proliferation,
three-dimensional tube formation, maturation, and sta-
bilization by vascular smooth muscle cells. Each step
is regulated by multiple cytokines and extracellular ma-
trix molecules [3,4]. It is well-established that fac-
tors secreted by mesenchymal stromal cells (MSCs) from
different sources regulate angiogenesis. For example, en-
dometrial MSCs promote angiogenesis after critical
hindlimb ischemia through secretion of growth factors
and matrix metalloproteinases [5]. Bone marrow derived
MSC-conditioned medium enhances endothelial cell and
smooth muscle cell proliferation and migration [6,7] and
promotes angiogenesis after hindlimb ischemia [8]. In
myocardial ischemic models, MSCs injected intraven-
ously or intracardially increase neovascularization and
improve heart function [9,10]. Transplantation of MSCs
also increases angiogenesis following experimental ische-
mic stroke [11-13] and traumatic brain injury [14].
SB623 cells are derived from marrow stromal cells
transfected with a plasmid expressing the human Notch1
intracellular domain (NICD1) [15]. SB623 cells express
all of the standard mesenchymal stromal cell markers
such as CD90, CD44, and CD105 and the expression of
NICD1 is transient [16]. Compared to MSCs, SB623
cells secrete higher levels of various paracrine factors
such as IL-6, IL-8, and MCP-1 [17]. SB623 cells have
been shown to reduce the lesion volume and promote
functional recovery when delivered to rodent brains fol-
lowing experimental focal ischemia [18]. Currently in an
FDA-approved Phase I/IIa clinical trial for chronic stroke,
SB623 cells are delivered stereotactically to the perinfarct
region (clinicaltrials.gov/ct2/show/NCT01287936). While
SB623 cell transplantation clearly aids the injured brain,
the exact mechanisms are yet to be elucidated. In the
current study, we compared the angiogenic potency of
SB623 -conditioned medium with the parental MSC-
conditioned medium using various in vitro models. In
addition, we begin to determine which secreted soluble
cytokines may be involved.
Methods
Materials
All reagents are from Life Technologies (Carlsbad, CA)
unless indicated otherwise. Human umbilical vein cells
(HUVECs) and Sprague–Dawley rats were purchasedfrom ATCC (Manassas, VA) and Charles Rivers Labora-
tories (Wilmington, MA), respectively.
Culture of MSCs and SB623 cells and preparation of
conditioned medium
Two human cell types were examined in this study; mes-
enchymal stromal cells (MSCs) and MSC-derived SB623
cells. Bone marrow aspirates from healthy human adults
were obtained from Lonza (Walkersville, MD), rinsed,
and plated in tissue culture flasks. Culture medium for
the generation and maintenance of donor cells was mi-
nimum essential alpha medium (α −MEM, Mediatech,
Herndon, VA) supplemented with 2mM Glutamine, 10%
fetal bovine serum (Hyclone, Logan, UT) and 1% penicil-
lin/streptomycin (referred to throughout the text as
“growth medium”). Non-adherent cells were discarded,
and the remaining cells were passed two times using
trypsin (0.25% + 2 mM EDTA). MSCs were then either
frozen for later use or plated for SB623 cell preparation.
For SB623 preparation, MSCs were transfected with the
pCI plasmid expressing the human Notch1 intracellular
domain (NICD; Notch1 truncated at the transmembrane
domain) and the neomycin-resistance gene using Fugene6
(Promega, Madison, WI) according to the manufacturer’s
protocol. The next day, the medium was replaced with
growth medium containing 100 μg/ml G418 and selection
continued for 7 days. Selection medium was then replaced
with growth medium. After removal of G418 and recov-
ery, cells were passed two additional times. SB623 cells
were harvested using trypsin-EDTA and cryopreserved for
later use. Both MSCs and SB623 cells were routinely char-
acterized by flow cytometry analysis and were found to be
positive (>95%) for CD29, CD90, and CD105, and negative
(<5%) for CD31, CD34, CD45, indicating their mesen-
chymal nature. For experiments, frozen MSCs and SB623
cells from the same human donor were thawed, re-plated
and allowed to recover for approximately one week. To
obtain conditioned medium, MSCs or SB623 cells were
cultured in growth medium to ~90% confluence (~15,000
cells/cm2). Following rinsing in phosphate-buffered saline
(PBS), the medium was replaced with Opti-MEMW me-
dium (~150,000 cells/ml), and the conditioned medium
was collected 72 hours later and stored at −80°C. At the
time of collection, the number of cells was quantified
(mean = 1.0 ± 0.1 million cells per flask, with no significant
differences between MSCs and SB623 cells). Frozen condi-
tioned medium samples were slowly warmed to 37°C on
the day of experimentation.
Angiogenic cytokine array of MSC- and SB623-
conditioned medium
To identify angiogenic trophic factors secreted by MSCs
and SB623 cells, the protein levels of specific factors
in donor cell-conditioned medium were measured. The
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Norcross, GA) was used to determine the concentrations
of the following 10 cytokines in MSC or SB623 cell-
conditioned media: angiogenin, angiopoietin-2, epider-
mal growth factor (EGF), fibroblast growth factor–2
(FGF-2/ bFGF), heparin binding-epidermal growth factor
like growth factor (HB-EGF), hepatocyte growth factor
(HGF), leptin, platelet derived growth factor-BB (PDGF-
BB), placental growth factor (PIGF), and vascular en-
dothelial growth factor (VEGF). To account for slight
differences in actual cell numbers, the data were norma-
lized to the cell number determined upon collecting
conditioned medium, and are thus expressed as protein
concentration per 1 million cells. For this assay, 4 diffe-
rent human donor pairs were tested.
Cell proliferation and survival of HUVECs
Two different lots of human umbilical vein endothelial
cells (HUVECs) were purchased from ATCC. Experi-
ments comparing SB623-CM and MSC-CM were perfor-
med with one lot of HUVECs; experiments assessing
the effect of SU5416 on SB623-CM angiogenic activity
were performed with a second lot of HUVECs. Briefly,
HUVECs were plated in endothelial basal medium-2
/10%FBS plus endothelial cell growth supplement (EBM-
2/10%FBS plus ECGS) at 750,000 cells per 0.1% gelatin-
coated T-75 flask for 24 hours. To prepare for the
serum-growth factor withdrawal study, HUVEC mono-
layers were rinsed twice with warm PBS and incubated
with fresh 12 ml EBM-2 medium for 16–24 hours at
37°C, 5% CO2. Serum-growth factor withdrawal was ini-
tiated by re-feeding each flask with 6 ml of EBM-2
medium plus 6 ml OptiMEM (control) or 6 ml of EBM-
2 medium supplemented with 6 ml of either MSC- or
SB623 cell-derived conditioned OptiMEM. After 7 days,
non-adherent and adherent cells were collected, centri-
fuged at 1400 rpm for 5 minutes, and divided into three
fractions for the subsequent three staining analyses.
To quantify cell death, cells were stained with 5 μg/ml
of propidium iodide (PI) for 30 min at room tem-
perature and acquisition/analysis was done on FL-2 lo-
garithmic channel using BD FACS Calibur CellQuest
program. Staining for Bcl-2 (anti-apoptotic molecule)
and Ki67 (proliferation marker; BD Bioscience) was also
performed. Cells were fixed in 4% paraformaldehyde and
permeabilized with 0.1% Triton-X for one hour; after
staining with either fluorescein-conjugated antibody
against Bcl-2 or Ki67 for one hour on ice, samples were
washed, acquired, and analyzed on FL-1 channel on BD
FACS Calibur. For these assays, 3 different human donor
pairs were tested with 3 wells per group.
For experiments with VEGFR inhibitor, HUVECs were
pre-treated with 50 nM SU5416 (EMD Millipore, Billerica,
MA) in EBM-2 medium for 30 minutes. Medium wasthen changed to 50 nM SU5416-supplemented medium
containing 6 ml of EBM-2 medium plus 6 ml of SB623 cell
derived-conditioned medium. Analyses for cell prolifera-
tion and cell death were performed after 5 days in culture.
For these assays, SB623 cells from 3 different human do-
nors were tested with 3 wells per group.
HUVEC tube formation assay
HUVECs were cultured in α-MEM/0.5%FBS/2 mM glu-
tamine/pen-strep for 24 hours and stained with 1 μM
calcein dye (Life Technologies, Carlsbad, CA) prior to
use in a vascular tube formation assay. In each well of a
96-well flat bottom plate, 50 μl of reduced growth factor
(RGF)-Cultrex basement membrane extract (Trevigen,
Gaithersburg, MD) were incubated at 37°C for 45 minutes.
HUVECs were harvested using 0.25% trypsin-EDTA, rin-
sed, and re-suspended in α-MEM/2 mM glutamine/pen-
strep at 1×105 cells/ml. 75 μl of HUVECs plus 75 μl of
either MSC- or SB623-conditioned medium (from 3 dif-
ferent human donor pairs) was added to each well. The
negative control was HUVECs plus OptiMEM medium
only. Fluorescent (for calcein-stained conditions) or phase
contrast photographs were taken at 16 hours, for subse-
quent quantification of tube formation by an experimenter
blinded to the groups. A continuous, unbroken ring of
cells was considered a complete vascular tube. Where in-
dicated, 50 nM SU5416 treatment was done 30 minutes
prior to changing to 50 nM SU5416-supplemented SB623
cell derived-conditioned medium (from 3 different human
donors), 50 nM SU5416-supplemented OptiMEM with
10 ng/ml recombinant human VEGF (positive control),
or 50 nM SU5416-supplemented OptiMEM (negative
control). For this assay, 3–4 wells/ group were used and
the total number of tubes per well was quantified and
averaged.
Aortic ring assay
All procedures conformed to guidelines set forth in the
NIH Guide for the Care and Use of Laboratory Animals.
Adult Sprague–Dawley rats were euthanized prior to
dissection. After opening the chest and clamping off the
two ends, the aorta was removed and placed in ice-cold
α-MEM/pen-strep medium prior to removal of the adi-
pose external lining. Adipose-free aorta was rinsed twice
with ice-cold EBM-2/pen-strep medium before section-
ing into 1-mm-thick rings. The aortic rings were then
transferred to plates containing α-MEM/2 mM glutam-
ine/pen-strep medium and incubated at 37°C, 5% CO2
for 6 days to minimize the endogenous rat angiogenic
factors; fresh medium was replaced on day 3. On day 6,
the medium was replaced with α-MEM/pen-strep me-
dium and the culture was continued for an additional
24-hour period. On day 0 of the aortic ring assay, 50 μl
of RGF- basement gel was deposited per well of a
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placed in the middle of each well and over-layed with an
additional 25 μl of RGF-Cultrex basement membrane
extract. After the gel had solidified at 37°C, 5% CO2 for
30 minutes, 500 μl of α-MEM/2 mM glutamine/pen-
strep was added to each well and incubated for an add-
itional 30 minutes. To assess the angiogenic activity from
MSC- and SB623-derived trophic factors, 500 μl of condi-
tioned medium was added. As a negative control, 500 μl
of unconditioned OptiMEM medium was used. Phase
contrast photos were taken at 7 or 10 days and both vessel
outgrowth and branching was quantified by an experi-
menter blinded to the experimental group. For this assay,
7 different human donor pairs were tested. To see the
effect of VEGFR inhibitor on SB623-conditioned medium
aniogenic activity, aortic rings were pre-treated with 50
nM SU5416 at 5% CO2/37degrees for 30 minutes; subse-
quently, medium was replaced with 50 nM SU5416-
supplemented SB623-conditioned medium (from 1 repre-
sentative donor). Each round of the assay included 3–4
wells per group (MSC-CM, SB623 CM, unconditioned
medium, or SB623 CM+ SU5416) that were quantified
and averaged.
Statistics
For each experiment (which included 3–4 wells/group),
a mean value was obtained for: (1) the treatment condi-
tion for each cell type (either MSCs or SB623 cells; one
value per human donor tested) and (2) the untreated
group (one value for each round of testing). For statis-
tical comparison (SigmaStat, StyStat Software, San Jose,
CA) each of these values were used and comparisons
were made using one way ANOVA between the follow-
ing groups (1) Control (unconditioned medium; n = 3),
(2) MSC-conditioned medium (n = 3-7); and (3) SB623
cell-conditioned medium (n = 3-7). Additional pair-wise
comparisons were made using Tukey’s test. An alpha
value of 0.05 was used to assess if the means were sig-
nificantly different.
Results
MSCs and SB623 cells secrete multiple pro-angiogenic
factors
Previously, Tate et al. demonstrated that VEGF is among
the trophic factors secreted in abundance by MSCs and
SB623 cells [17]. In the current study, using an angio-
genic cytokine array to compare SB623 cell- and its cor-
responding parental MSC-conditioned medium (CM)
from four different human donors, we assessed the se-
cretion of 10 angiogenic cytokines (expressed as protein
concentration per million cells). Nine of the 10 angio-
genic factors tested were detected in MSC- and SB623
cell-conditioned media (Figure 1). Due to high variability
across donors, there were no significant differences inprotein levels between SB623 CM and parental MSC-
CM. However, angiogenin, angiopoetin-2, and HB-EGF
were consistently found in higher levels in SB623-CM
compared to their respective parent MSC-CM while
PlGF was consistently lower for all four donors tested.
Both MSCs and SB623 cells secrete relatively high levels
of the prototypic angiogenic protein, VEGF, compared to
the other proteins examined.
MSC- and SB623-derived factors support HUVEC survival
and proliferation
An occlusion to the middle cerebral artery leads to a re-
duction in nutrients important not only to neural cells
but also vascular cells. To determine if soluble factors
from SB623 cells and MSCs have protective effect on
nutrient-deprived endothelial cells, we cultured HUVECs
in medium deprived of serum and growth factors for 24
hours prior to exposure to SB623- or MSC- conditioned
medium (CM), or serum-reduced OptiMEM (negative
control). After 5–7 days, cell death was assessed by pro-
pidium iodide staining and analyzed by flow cytometry. In
the control condition where nutrient-deprived HUVECs
were cultured in OptiMEM medium for 7 days, more than
70% of cells were positive for propidium iodide staining.
Addition of either SB623- or MSC-conditioned medium
significantly reduced the percentage of propidium iodide
positive cells (p < 0.05; Figure 2A). Consistent with these
results, we observed a significantly higher protein expres-
sion of Bcl-2, a pro-survival regulator, in HUVEC cells res-
cued by either SB623- or MSC-conditioned medium,
compared to the control (p < 0.05; Figure 2B). By intracel-
lular staining with a fluorochrome-conjugated antibody
against Ki67, an indicator of cell division, followed by flow
cytometry acquisition/analysis, we demonstrate that Ki67
expression was significantly increased when comparing
the control cultures versus the SB623- or MSC-conditio-
ned medium-rescue cultures (p < 0.05; Figure 2C). There
were no significant differences in cell survival, Bcl-2, or
Ki67 expression between HUVEC cultures rescued with
SB623-CM versus MSC-CM. Collectively, the results de-
monstrate that SB623-conditioned medium is as effective
as the parental MSC-conditioned medium in supporting
the survival and proliferation of HUVECs.
MSC- and SB623-derived factors enhance vascular tube
formation
To re-establish the cerebral blood flow, the surviving
and proliferating endothelial cells must receive external
signals prompting their migration and invasion to form
a complex vasculature. Using the well-established 3D-
HUVEC vascular tube formation assay, we compared the
potency of SB623 cell- versus MSC-conditioned medium
in promoting complete vascular tubes after 16 hours in













































































Figure 2 SB623 cell- and MSC-conditioned medium supports HUVEC survival and proliferation. Following “starvation”, HUVECs were
cultured for 7 days with OptiMEM conditioned by either MSCs or SB623 cells or unconditioned OptiMEM (“Control”). A) Compared to
unconditioned medium, conditioned medium (CM) led to a significant decrease in dead/dying propidium iodide-positive HUVECs. B) There was a
significant increase in expression of Bcl-2, indicating that factors secreted by MSCs or SB623 cells are anti-apoptotic for HUVECs. C) Compared to
































































































































  MSC SB623 
pg/ml/million cells AVG SD AVG SD 
Angiogenin 741 178 985 271 
ANG-2 540 252 641 275 
EGF <LOD n/a <LOD n/a 
bFGF 53 7 40 17 
HB-EGF 205 162 282 228 
HGF 123 55 143 75 
Leptin 397 226 437 213 
PDGF-BB 18 22 16 18 
PIGF 300 178 171 85 
VEGF 30,503 9,229 38,119 8,692 
Figure 1 MSCs and SB623 cells secrete pro-angiogenic factors. The table shows average concentration of angiogenic cytokines found in
OptiMEM conditioned for 72 hours by either MSCs or SB623 cells from 4 matched human donor lots. Note the relatively high expression of VEGF
compared to other cytokines present. Grey highlights indicate factors which are consistently different between MSCs and SB623 cells. These 4
cytokines are plotted by donor showing that, though there is a lot of donor variability, there are consistent trends across multiple donors.
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CM or MSC-CM increased the number of complete
HUVEC tubes compared to the negative control. Similar
to the above survival and proliferation results, there were
no significant differences in the potency of SB623-CM
versus MSC-CM in this process.
MSC- and SB623-derived factors enhance angiogenesis in
a rat aortic organotypic model
Under physiological conditions, endothelial cell prolifer-
ation and sprouting are activated by a spectrum of sig-
nals emanating from various cell types, including the
monocyte/macrophages and the vascular smooth muscle
cells. Therefore, to test the angiogenic potency of SB623
cell- and MSC-conditioned medium in a more physiolo-
gically relevant model than the HUVEC model, aortic
rings from adult rats were generated. To minimize the
production and carry-over of endogenous rat angiogenic
factors induced in response to the slicing injury, the aor-
tic rings were cultured in serum-free medium for a week
prior to transfer onto a commercially available reduced-
growth factor basement matrix for testing. After 7–10
days in the matrix, we noted a low number of sprouts
and branches from the controls which were not exposed
to CM of either SB623 cells or MSCs. In contrast, there
was an increase in both the number of newly sprouted
vessels and branching points from the aortic rings ex-
posed to SB623 cell- and MSC-conditioned medium
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Figure 3 SB623 cell and MSC-conditioned medium enhances HUVEC t
either MSCs or SB623 cells or unconditioned OptiMEM (“Control”). Compare
tubes formed within 16 hours in the presence of conditioned medium (CM
HUVECs (labeled “complete tubes”) in the entire well (96-well plate; 3–4 weamount of branching in cultures with SB623 cell-CM
(but not with MSC-CM) compared to control condi-
tions. These results demonstrate that, in a physiologic-
ally relevant 3D model, soluble factors from SB623 cells
may be more potent in angiogenesis than soluble factors
from the parental MSCs.
Blocking VEGF signaling reduces but does not abrogate
the angiogenic activity of SB623-CM
From the angiogenic cytokine array results, we demon-
strate the presence of multiple angiogenic factors in
addition to VEGF. To tease out the contribution of
VEGF, we blocked VEGFR2 downstream signaling using
SU5416 in the HUVEC and aortic ring assays to mea-
sure the angiogenic potency of non-VEGF cytokines pre-
sent in SB623-CM. In the HUVEC model, a dose of
50 nM SU5416 has previously been shown to reduce
VEGFR2-mediated endothelial cell proliferation with lit-
tle impact on other receptor tyrosine kinases [19]. Here,
we demonstrate that, pre-treatment with 50 nM SU5416
reduced, but did not abrogate, the pro-survival and prolif-
erative activity of SB623 cell-CM on HUVECs (Figure 5A
and B). In contrast, this dose was sufficient to reverse the
ability of SB623 cell-CM to induce of HUVEC tube for-
mation, highlighting the strong dependence of HUVEC
cell migration and invasion on VEGFR2 activation
(Figure 5C). Similarly, when applied to serum-starved aor-
tic rings prior to addition of SB623 cell-CM, this dose





ube formation. HUVECs were cultured with OptiMEM conditioned by
d to unconditioned medium, there were more complete vascular
). The average number of completely-enclosed rings formed by the













































Control MSC CM SB623 CM 
Figure 4 Branching of new vessels is enhanced by MSC- and SB623 cell-secreted factors. Following suppression of endogenous
outgrowth, rat aortic rings were plated in gels with either OptiMEM (“Control”) or OptiMEM conditioned by MSCs or SB623 cells. After 7–10 days,
there were more vessels with conditioned medium and significantly more branching points in SB623 CM versus OptiMEM only (*p < 0.05).
Representative images of aortic rings after 7 days in culture with OptiMEM only, or MSC-conditoned medium, or SB623-conditioned
medium. Mean ± SEM.
Dao et al. Journal of Translational Medicine 2013, 11:81 Page 7 of 11
http://www.translational-medicine.com/content/11/1/81VEGFR2-dependent pathway in this process (Figure 5D).
These results underscore the complexity of angio-
genic events with some steps being more dependent on
VEGFR2 signaling than others.
Discussion
Transplantation of SB623 cells, a derivative of marrow
stromal cells, into animal models of stroke elicited func-
tional recovery [18]. As there is strong correlation be-
tween angiogenesis and functional improvement in stroke
patients [20], we hypothesized that the secretome of
SB623 cells could include angiogenic factors. Using an an-
giogenic factor antibody array, we identified a panel of
pro-angiogenic factors differentially secreted by SB623
cells and the corresponding parental MSCs. For instance,
angiogenin, angiopoietin-2, HB-EGF, and VEGF levels
were consistently detected at higher levels in SB623-
conditioned medium than the parental MSC-conditioned
medium, with VEGF being present at highest levels
(>30 ng per million of SB623 cells) compared to the
other three factors (< 1 ng per million of SB623
cells). Angiogenin has been reported to enhance endo-
thelial cell invasiveness during migration by stimulatingthe proteolytic activities in cultured endothelial cells
[21]. The presence of angiogenin in endothelial cells
was suggested to be important for VEGF-mediated
cell proliferation [22]. Angiopoietin-2 has been com-
monly described as an anti-angiogenic factor, destabilizing
the vasculature and promoting endothelial cell death.
However, in the presence of VEGF, angiopoietin-2 adopted
the pro-angiogenic function, promoting the sprouting of
new blood vessels as well as the increase in the capillary
diameter [23]. Unlike angiogenin and angiopoietin-2, HB-
EGF was shown to act on smooth muscle cells, stimulat-
ing their production of VEGF which in turn promotes
endothelial cell proliferation [24]. Identification of these
factors along with others such as PlGF, HGF, and leptin
listed in Figure 5 supports the hypothesis that SB623 cells
promote angiogenesis after stroke.
To validate the angiogenic activity present in SB623
secretome, we initiated various functional assays. First, to
mirror the nutrient stress condition after stroke, we used
a serum and growth factor-deprived model of HUVECs
and measured the protective effect of SB623 on endothe-
lial cells. By staining for propidium iodide (to measure
cell death), Bcl-2 (an anti-apoptotic molecule), and Ki67
Control
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Figure 5 (See legend on next page.)
Dao et al. Journal of Translational Medicine 2013, 11:81 Page 8 of 11
http://www.translational-medicine.com/content/11/1/81
(See figure on previous page.)
Figure 5 Treatment with 50nM SU5416 reduces angiogenic potency of SB623 cell -conditioned medium. Following “starvation”, HUVECs
were treated with SB623-CM with or without SU5416 for 30 minutes prior to culture to assess the role of VEGF in different steps of angiogenesis.
The negative controls were cultured directly in OptiMEM. A and B) Cell death and cell proliferation were assessed after 7 days in culture by
staininig for propidium iodide and Ki67, respectively. SB623 cell-CM significantly reduced cell death and increased proliferation (*p < 0.05
versus OptiMEM only control). However, this was partially reversed in the presence of SU5416 (#p < 0.05 SB623 CM versus SB623 CM + SU5416).
C) HUVEC vascular tube formation was quantified at 16- and 40 hours after plating in RGF-basement gel. A representative phase contrast picture
of vascular tube formation at 16 hours is shown here, revealing the reduction in complete tubes formed in the presence of SU5416 (p < 0.05
versus OptiMEM only control; #p < 0.05 versus SB623 CM + SU5416). D) Aortic rings were likewise pre-treated with or without SU5416 for
30 minutes prior to embedding in RGF gels with SB623-CM. The control aortic ring well was not pre-treated with SU5416 and was maintained in
RGF-basement gel in OptiMEM. It is clear that in the presence of SU5416 there is no aortic sprouting. Plots show Mean ± SD.
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onstrated that conditioned medium from SB623 cells
effectively promotes the survival and proliferation of
nutrient-starved HUVECs; this effect was comparable
to conditioned medium from MSCs. From the cyto-
kine array results, VEGF is the angiogenic factor se-
creted at highest levels by MSC and SB623 cells. We
therefore pre-treated HUVECs with 50 nM SU5416, a
concentration previously reported to reduce VEGF medi-
ated cell survival and proliferation without affecting the
activity of other angiogenic factors such as bFGF or PDGF
([19]. The results demonstrated a 50% reduction in both
cell survival and proliferation in SU5416 treated HUVECs
cultured with conditioned medium from MSC or SB623
cells. The fact that we did not observe complete inhibition
of cell survival and proliferation raises two possibilities.
First, bFGF has been shown to be a potent mitogen and
survival factor for endothelial cells [25]. Hence, the low
levels of bFGF present in SB623-conditioned medium
along with other angiogenic factors whose action did not
depend on VEGFR2 signaling could account for the re-
sidual cell survival and proliferation. And second, as VEGF
can promote this cellular effect through FLT1 and studies
have demonstrated that a dose of 50nM SU5416 did not
inhibit FLT1 signaling [26] it is possible that VEGF-FLT1
signaling could elicit some effect on endothelial cell sur-
vival and proliferation. Collectively, the results demon-
strated that SB623-derived trophic factors support the
proliferation and survival of nutrient deprived endothelial
cells and implicated VEGF as a major player in this
process.
To restore nutrient and oxygen supply to the brain
after stroke, the vasculature must be reinstated, starting
with endothelial cell migration and sprouting. Using the
HUVEC vascular tube formation assay which measures
cell migration and invasion, we demonstrated that vas-
cular tube formation was enhanced by conditioned me-
dium from both SB623 cells and parental MSCs when
compared to negative control. We next investigated the
angiogenic activity of SB623-derived CM in a rat 3D aor-
tic ring assay; this angiogenic model is more physiologic-
ally relevant as it contains both endothelial and vascular
smooth muscle cells. One of the complications of theaortic ring assay is that there are endogenous angiogenic
factors released by cells after preparation of the aortic
rings [27]. To minimize the levels of endogenous factors,
we therefore pre-cultured the aortic rings in serum-
free endothelium medium for one week followed by a
24-hour culture in α-MEM, a medium containing ascor-
bic acid prior to use in angiogenic assay. Addition of
SB623 cell- and MSC-CM both enhanced endothelial
cell sprouting from the aortic rings. Of note, there was a
higher degree of branching per sprout in conditions trea-
ted with SB623 cell-CM compared to MSC-CM. Bran-
ching of endothelial sprouts is important in establishing a
complex vascular system; increased branching would pro-
vide a wider area of oxygen and nutrient supply to the
brain. To determine the role of VEGF-KDR signaling role
in endothelial cell migration and sprouting, 50nM SU5416
was added to both the HUVEC vascular tube formation
assay and the aorting ring assay. In both models, this low
dose of SU5416 completely reversed the migrating- and
sprout-inducing activity of SB623 cell-CM. This is consis-
tent with an earlier study showing that VEGF is a key
regulator of endothelial cell migration and sprouting du-
ring angiogenesis and that this process is most efficient
through KDR, not FLT1 [26].
It is interesting that SB623 cell-CM was superior to
MSC-CM in promoting angiogenesis in the rat aortic
ring assay, and not in the HUVEC assay. This observa-
tion is likely due to differences in the two assays. For in-
stance, in the HUVEC assay, the only cells responsive to
the exogenous CM are the human endothelial cells. In
contrast, in the aortic ring assay, the responding cells in-
clude not only the endothelial cells but also the vascular
smooth muscle cells and the macrophages, both of which
are key players in angiogenesis. For instance, angiopoietin-
2 which is consistently higher in SB623-CM than parental
MSC-CM have been shown to increase the inherent an-
giogenic properties of macrophages [28]. CCL-2, a chemo-
kine upregulated in SB623 cell-CM [17] is mitogenic to
macrophages and thus, could synergize with angiopoietin-
2 in amplifying the proangiogenic activity of aortic ring as-
sociated macrophages. IL-6 and IL-8, also upregulated in
SB623-CM [17] have been shown to stimulate vascular
smooth muscle cells [29,30], which in turn can amplify
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co-cultures of HUVECs with smooth muscle cells and/or
HUVECs with macrophages may give better insights into
the mechanism of actions of SB623 cell-CM in the rat aor-
tic ring assay.
Conclusions
A panel of angiogenic paracrine factors differentially
secreted by SB623 cells and the parental MSCs was
identified using the Quantikine Angiogenesis Array.
In the HUVEC assay and the aortic ring assay, SB623-
conditioned medium is equally as potent in promoting
endothelial tube formation and endothelial cell sprouting
as MSC-conditioned medium. This functional aspect of
SB623 cells may be one of the mechanisms by which
SB623 cell transplantation promotes repair and regene-
ration in experimental stroke.
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